<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04184713</url>
  </required_header>
  <id_info>
    <org_study_id>HULP 5358</org_study_id>
    <nct_id>NCT04184713</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of an Specific Oral Nutritional Supplement on the Nutritional Status in Cancer and Malnutrition</brief_title>
  <official_title>A Clinical Trial With Nutritional Intervention to Evaluate the Effect of an Specific Oral Nutritional Supplement on the Nutritional Status in Patients With Cancer and Malnutrition</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Adventia Pharma, S.L.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effect of a specific nutritional oral supplement on the nutritional status of patients with
      cancer and malnutrition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multicentric, parallel, randomized, double blind and controlled clinical-nutritional study of
      8 weeks of duration and 2 study groups of treatment: Experimental group (experimental
      nutritional oral supplement); and Control group (control nutritional oral supplement) to
      evaluate the effect on the nutritional and functional status, the quality of life and body
      composition of patients with cancer and malnutrition undergoint specficic treatment
      (chemotherapy, radiotherapy, inmunotherapy).
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nutritional status</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>Subjective Global Assessment (SGA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diet quality</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>72h food registry questionaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional status</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>Dinamometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eastern Cooperative Oncology Group Scale (ECOG)</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>Eastern Cooperative Oncology Group Scale (ECOG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body composition</measure>
    <time_frame>Change from baseline to day 142</time_frame>
    <description>BIA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Malnutrition</condition>
  <condition>Cancer</condition>
  <condition>Nutrition Related Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Experimental Group</intervention_name>
    <description>Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber and omega-3 enriched, with L-leucine, betaglucans and medium chain triglycerides) for 8 weeks.</description>
    <arm_group_label>Experimental Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control Group</intervention_name>
    <description>Nutritional intervention and physical activity recommendations. Consumption of 2 tetra paks/day of a specific oral nutritional supplement (hypercaloric/hyperproteic with fiber) for 8 weeks.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women over 18 with a cancer diagnosis (any type).

          -  Subjects who have initiated during the next mont a treatment with chemo and or
             radiotherapy with or without surgery.

          -  Having lost more than 5% of body weight in the last 6 months.

          -  Adequate cultural level and understanding for the clinical trial.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Subjects who are participating in other clinical trials.

          -  Subjects with morbid obesity.

          -  Subjects who will undergo surgery or who will undergo.

          -  Subjects with cachexia

          -  Subjects with infection of a cause other than of the tumor

          -  Subjects with an infectious process

          -  Subjects with Diabetes Mellitus treated with insulin and/or not controlled

          -  Subjects with kidney, heart, respiratory or liver disease.

          -  Subjects with autoimmune diseases.

          -  Subjects with mental illness or decrease function cognitive.

          -  Subjects who consume oral supplements or artificial nutrition and who cannot be
             withdran at least 1 week before startint the study.

          -  Patients who have consumed food supplements or fortified foods in omega 3 (arginine or
             nucleotides) during the previous month.

          -  Patients who reject oral supplements.

          -  Pregnant or breastfeeding women.

          -  Allergic to any component of the formula
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carmen Gómez Candela, Msc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Paz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute for Health Research IdiPAZ</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 12, 2019</study_first_submitted>
  <study_first_submitted_qc>November 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 4, 2019</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>malnutrition</keyword>
  <keyword>cancer</keyword>
  <keyword>nutrition</keyword>
  <keyword>nutritional oral supplement</keyword>
  <keyword>clinical trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

